Semaglutide can help the body make more insulin and improves insulin sensitivity, which in turn lowers blood-glucose levels ...

Learn about semaglutide’s effectiveness and clinical trial results and whether it could be right for you in your MASH ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...

The MarketWatch News Department was not involved in the creation of this content.-- Wegovy(R) (semaglutide injection) granted conditional marketing authorization for the treatment ...

Introducing Ozempic, a groundbreaking GLP-1 agonist now making waves in India! This innovative treatment emulates a natural ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...

Denmark: Novo Nordisk and Akero Therapeutics have announced that Novo Nordisk's acquisition of Akero has been completed.With ...

MedPage Today brought together three hepatology experts for a virtual roundtable discussion on metabolic ...

The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...

Altimmune, Inc. nears key MASH data for pemvidutide—learn investor risks, potential rewards, and what the upcoming results ...

This follows recent successful efforts by the Trump administration to cut the price of this compound for certain patients. Semaglutide is Novo Nordisk's largest growth driver, and it has not performed ...